Company profile: Yposkesi
1.1 - Company Overview
Company description
- Provider of CDMO services for gene and cell therapy, including cGMP manufacturing of AAV and lentiviral vectors (clinical and commercial batches), upstream and downstream bioprocess development, analytical development with assay qualification and validation, cGMP fill & finish, regulatory support, and the LentiSure platform to optimize yields, productivity, and transduction efficiency.
Products and services
- Bioprocess Development (USP & DSP): Engineers upstream (USP) and downstream (DSP) bioprocesses to enhance production efficiency for gene and cell therapies via a custom-engineered development approach
- CGMP Manufacturing of AAV and Lentiviral Vectors: Produces clinical and commercial batches of AAV and lentiviral vectors in compliance with current Good Manufacturing Practices (cGMP), delivering industrial-grade batch manufacturing
- LentiSure™: Lentiviral vector manufacturing platform architects processes to optimize higher yields and ensure high productivity and transduction efficiency, utilizing a platform-level design
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Yposkesi
Crown Laboratories
HQ: United States
Website
- Description: Provider of consumer healthcare products, prescription products, and contract development and manufacturing services as a fully integrated specialty pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crown Laboratories company profile →
Defence Therapeutics
HQ: Canada
Website
- Description: Provider of biopharmaceutical innovations leveraging Accum™ technology, a drug delivery platform that enhances delivery of therapeutic agents to target cells to improve efficacy for cancer and infectious diseases. Offerings include cancer therapeutics, vaccine development for infectious diseases and cancers, antibody-drug conjugates, AccuTOX, and the ARM-002 anti-cancer vaccine shown effective in pre-clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Defence Therapeutics company profile →
Reverba
HQ: United States
Website
- Description: Provider of patient engagement solutions for pharmaceutical and biotechnology companies, including clinical patient engagement programs powered by the reverbaBRIDGE platform, global clinical trial optimization with patient-centered approaches and real-time data insights, expert recruitment, tech-enabled relationship management and automation, and total compliance with HIPAA, GDPR, and FDA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reverba company profile →
Syner-G BioPharma
HQ: United States
Website
- Description: Provider of pharmaceutical development and CMC solutions; cGMP and quality/compliance services; regulatory strategy and submissions spanning CMC, nonclinical, and clinical; functional outsourcing partnerships with dedicated regulatory staff; medical writing for scientifically accurate, compliant documents; and CMC consulting focused on strategy, compliance, and process optimization in drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syner-G BioPharma company profile →
Adalvo
HQ: Malta
Website
- Description: Provider of B2B pharmaceutical products and services, part of Alvogen Group and powered by Alvogen and Alvotech. Offers 90+ specialty generic small-molecule products across Oncology, Women’s Health, Cardiovascular and CNS; 15+ value-added 505(b)(2) CNS therapies; and 8+ peptide products for Rare Diseases and Diabetes. Develops Fidaxomicin 200 mg tablets, Ethinylestradiol/Drospirenone, and Dimethyl Fumarate for RRMS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adalvo company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Yposkesi
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Yposkesi
2.2 - Growth funds investing in similar companies to Yposkesi
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Yposkesi
4.2 - Public trading comparable groups for Yposkesi
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →